Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies.
Saved in:
| Title: | Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies. |
|---|---|
| Authors: | Wang, Kun1 (AUTHOR), Pan, Chaohsuan2 (AUTHOR), Xu, Fengyan1 (AUTHOR), Tse, Archie N.2 (AUTHOR), Sheng, Yucheng2 (AUTHOR) shengyucheng@cstonepharma.com |
| Source: | British Journal of Clinical Pharmacology. Mar2025, Vol. 91 Issue 3, p748-760. 13p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
